INOVIO
Manufacturing · Pennsylvania, United States · 51-200 Employees
View Company Info for Free
Overview
Headquarters
660 W Germantown Pike Ste 110, Plymouth ...Phone Number
(267) 440-4200Website
www.inovio.comRevenue
<$5 MillionStock Symbol
INOIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
4
3
1
1
1
1
About INOVIO
Inovio Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops active DNA immunotherapies and vaccines in combination with proprietary electroporation delivery devices to prevent and treat cancers and infectious diseases. Its SynCon immunotherapy design has the ability to break the immune systems tolerance of cancerous cells; and SynCon product design is also intended to facilitate cross-strain protection against known, as well as new unmatched strains of pathogens, such as influenza. It has completed, current or planned clinical programs of its proprietary SynCon immunotherapies for HPV-caused pre-cancers and cancers, influenza, prostate cancer, breast/lung/pancreatic cancer, hepatitis C virus, hepatitis B virus, HIV, Ebola, Middle East Respiratory Syndrome, and Zika virus. The companys partners and collaborators include MedImmune, LLC, the Wistar Institute, University of Pennsylvania, Defense Advanced Research Projects Agency, GeneOne Life Science, Plumbline LifeRead more
INOVIO Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is INOVIO your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Earning: See what the market has to say on INOVIO recently announced quarterly report
Product Launch: Get notified when INOVIO launches new products
Check if INOVIO has recently received funding, and reach out quickly before it becomes old news!
INOVIO, which may be a good buyer, showed buying intent in Masked Content Topic
Website visits: Recent activity has been detected on your website
Congratulate Masked Content for being promoted to Masked Content at INOVIO
Check out if INOVIO is spiking on competitors!
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Funding: Get notified immidiatlly once INOVIO has new funding data
Click to see if INOVIO had a recent Job posting/layoffs
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 2 more new buyers
Compare Similar Companies to INOVIO
Compare insights from companies similar to INOVIO, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
$1.4B
201-500
Public
$1.1B
1998
$114.2M
51-200
Public
$462.1M
1994
JB
Jennifer BuellPresident and CEO of MiNK Therapeutics, Chairman, Executive Council At Agenus
Company Profile Activity
Activity Insights
INOVIO is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
INOVIO is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about INOVIO.
INOVIO financials insights
Gather financial insights about INOVIO, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2013
Stock Offering
$14M
Grant
$3.5M
2014
Stock Offering
$59.2M
2015
Stock Offering
$82.1M
Grant
$24M
2017
Stock Offering
$70.2M
2018
Grant
$56M
2019
Multiple Rounds
$98.9M
2020
Grant
$5M
INOVIO Tech Stack
A closer look at the technologies used by INOVIO
See more technologies
Most Recent Scoops
Earnings
INOVIO has reported operating expenses of $21.9 million for Q1 2026, a 13% decrease compared to $25.1 million in Q1 2025, and a net loss of $19.7 million, or $0.28 per share basic and dilutive, compared to a net loss of $19.7 million, or $0.51 per share basic and dilutive, for Q1 2025.
Earnings, Finance
Project
INOVIO has reported that the FDA completed its standard mid-cycle review of the BLA for INO-3107 with no new significant issues raised, and has scheduled the late-cycle review for Q3, as the BLA continues its active review under the Accelerated Approval Program.
Pharmaceuticals
Project
INOVIO is advancing its commercial readiness plans in anticipation of a potential US approval of INO-3107 in 2026, having completed targeting, segmentation, and product positioning work, and having engaged key commercial partners including a third-party logistics provider, specialty distributor, specialty pharmacy, patient hub, and agency of record, with plans to manage commercialization with the support of a contract sales organization.
Partnership, Product Marketing, Product Launch, Sales
Earnings
finished Q1 2026 with $37.7 million in cash equivalents and short-term investments, compared to $58.5 million as of December 31, 2025, and with the addition of the April 2026 public equity offering, has extended its estimated cash runway into Q1 2027, beyond the target PDUFA date of INO-3107, with an operational net cash burn estimate of approximately $18 million for Q2 2026.
Earnings, Spending/Investment, Business Finance, Finance, Financing & Debt
Project
Events, Research & Development, Medical Research, Pharmaceuticals
INOVIO News & Media
Inovio Pharmaceuticals Shareholders Back Board as INO-3107 FDA Review Advances
Inovio Pharmaceuticals (NASDAQ:INO) shareholders approved all proposals presented at the company’s 2026 annual meeting, including the election of eight directors and the ratification of Ernst & Young LLP as the company’s independent registered public accounting firm for the year ending Dec. 31,Positive Topline Results from a Phase 3 Trial for VGX-3100 in Cervical Dysplasia Patients Announced by ApolloBio, INOVIO's Partner in China
Results provide important clinical evidence to support ApolloBio's future regulatory submission in China of VGX-3100, INOVIO's DNA immunotherapy candidate ApolloBio's new clinical results further highlight the potential of INOVIO's DNA medicine platform to treat diseases caused by...INOVIO CMO vests RSUs, uses shares for taxes | INO Insider Trading - Stock Titan
INOVIO CMO Michael Sumner reports 2,385 RSUs converting to stock on May 15, 2026, with 680 shares withheld by the company to cover tax obligations, leaving 35,961 shares held.INOVIO Reports First Quarter 2026 Financial Results and Recent Business Highlights
Biologics License Application (BLA) for INO-3107 actively being reviewed under the accelerated approval program by the U.S. Food and Drug Administration (FDA) with a target Prescription Drug User Fee Act (PDUFA) date of October 30, 2026 Commercial readiness plans continue to advance in...
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding INOVIO
Sign Up For FreeTo access detailed company insights
Inovio Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops active DNA immunotherapies and vaccines in combination with proprietary electroporation delivery devices to prevent and treat cancers and infectious diseases. Its SynCon immunotherapy design has the ability to break the immune systems tolerance of cancerous cells; an... Read More
